OraSure Technologies Inc. (OSUR)
NASDAQ: OSURHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OSUR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $238.90M
- EPS (TTM)
- -$0.69
- Dividend yield
- None
- Ex-dividend date
- Jan 8, 1998
- 52-week range
- 2.28 – 4.58
- Day range
- 3.40 – 3.61
- Volume / Avg
- 502.79K / 571.50K
- Beta
- —
- Shares outstanding
- 69.05M
52-week range
OSUR stock today
OraSure Technologies (OSUR) closed at $3.46 on Nov 20, down 4.16% (-$0.15), versus the S&P 500's 3.70% decline. Shares are 24.5% below their 52-week high of $4.58, set on Jun 17, 2026 and 51.8% above the 52-week low of $2.28, in the middle of the past year's range. OSUR is up 43.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 52.4%.
OraSure Technologies has posted a net loss over the last twelve months (EPS of -$0.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About OraSure Technologies
Company profileOraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Ms. Carrie Eglinton Manner
- Headquarters
- Bethlehem, PA
- Employees
- 500
- Website
- orasure.com
Financial highlights
Full financialsIn fiscal 2025, OraSure Technologies generated $115.0 million in revenue, down 38.1% from fiscal 2024, its first annual decline since 2024. OraSure Technologies reported a net loss of $68.7 million, compared with a loss of $19.5 million a year earlier. Gross margin was 41.9% (down from 42.7%) and operating margin -62.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $115.02M | $185.83M | $405.47M | $387.48M | $233.67M |
| Growth | -38.10% | -54.17% | +4.64% | +65.82% | +36.08% |
| Net income | $-68.73M | $-19.50M | $53.66M | $-17.13M | $-23.00M |
| EPS (diluted) | $-0.94 | $-0.26 | $0.72 | $-0.24 | $-0.32 |
Analyst forecast
ForecastConsensus (2 analysts)
buy
Avg. price target
$5.50+58.96%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.17 vs $-0.22
- Surprise
- +22.73%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $1.60
- Ex-dividend date
- Jan 8, 1998
OSUR news
All OSUR news- OraSure (OSUR) Q3 2026 Earnings Call TranscriptNasdaqOSUR, HEI.A
- OraSure Technologies, Inc. Reports Third Quarter 2026 Net Revenues of $30.9 millionNasdaq
- OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin ExpansionGlobeNewswire
- OraSure Technologies Consensus Price Target Raised 37.50% to $5.61Nasdaq
- OraSure Technologies rejoint la Coalition mondiale contre la drépanocytose afin de favoriser l’accès à un diagnostic plus précoce et aux soinsGlobeNewswire
- OraSure Technologies تنضم إلى التحالف العالمي لمكافحة مرض الخلايا المنجلية لتعزيز فرص التشخيص المبكر والحصول على الرعاية الصحيةGlobeNewswire
- OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and CareGlobeNewswire
- OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9thGlobeNewswire
OraSure Technologies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PROFProfound Medical Corp. | 6.38 | -3.19% | $233.68M | vs OSUR |
| OFIXOrthofix Medical Inc. | 6.07 | -4.26% | $247.41M | vs OSUR |
| SSIISS Innovations International Inc. | 1.27 | -0.78% | $254.86M | vs OSUR |
| CLPTClearPoint Neuro Inc. | 6.91 | -5.47% | $221.49M | vs OSUR |
| NPCENeuropace Inc. | 7.95 | -2.33% | $273.89M | vs OSUR |
| KTWOK2 Capital Acquisition Corporation Class A | 10.13 | 0.00% | $203.02M | vs OSUR |
| PDEXPro-Dex Inc. | 63.00 | -0.77% | $201.60M | vs OSUR |
| UTMDUtah Medical Products Inc. | 69.49 | -2.07% | $198.01M | vs OSUR |
Indexes, lists and sector
OraSure Technologies stock FAQ
What is OraSure Technologies's stock price today?
OSUR last traded at $3.46 as of Nov 20, 4:00 PM EST, down 4.16% on the day. Prices are delayed at least 15 minutes.
Does OraSure Technologies pay a dividend?
Yes. OraSure Technologies pays $0.00 per share annually. The most recent dividend of $1.60 had an ex-dividend date of Jan 8, 1998.
Who is OraSure Technologies's CEO?
Ms. Carrie Eglinton Manner is the chief executive officer of OraSure Technologies Inc., which has about 500 employees.
Has OSUR ever split its stock?
Yes. The most recent OSUR stock split was a 3-for-1 split on Apr 8, 1987.
What is the OSUR 52-week high?
The 52-week high for OSUR is $4.58 and the 52-week low is $2.28. The stock is currently 24.5% below its high.